Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Our mission is to develop breakthrough therapies that improve the lives of people living with rare, chronic liver diseases.

Our vision is to become the premier biotechnology company focusing on rare, chronic liver diseases, providing innovative treatments to improve the lives of patients worldwide.

Mirum Pharmaceuticals has been recognized as one of the leading biotechnology companies developing treatments for rare, chronic liver diseases. The company has been the recipient of numerous awards from industry associations, academic institutions, and specialty medical societies.